Also, mutations in the ABL domain, which confer resistance to imatinib, can be detected in rare subpopulations of BCR-ABL-positive chronic myeloid leukemia (CML) (Shah et al, 2002). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.